Centro De Ingenieria Genetica Y Biotecnologia

Universidad Nacional De Quilmes

Biorec S.a.

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)

Universidad De Buenos Aires

Romikin S.a.

Biorec B.v.

Daniel Eduardo Gomez

Daniel Fernando Alonso

Boris Ernesto Acevedo Castro

Luis Javier González López

Lila Rosa Castellanos Serra

Jeovanis Gil Valdés

Lázaro Hiram Betancourt Núñez

Aniel Sánchez Puente

Jorge Fernández De Cossio Dorta Duque

Vladimir Besada Pérez

Yassel Ramos Gómez

Silvio Ernesto Perea Rodriguez

Arielis Rodríguez Ulloa

Yasser Perera Negrin

Ernesto J Podestá

Sergio H Szajnman

Juan B Rodriguez

Angela R Solano

Pablo Lorenzano Menna

Ulises D Orlando

Jessica G Prada

Ana F Castillo

Paula M Maloberti

Eduardo Francisco Far&iacute;ias

Elisa Dora Bal De Kier Joff&eacute;

Santiago Giron

Giselle V Ripoll

Arielis Rodriguez Ulloa

Yasser Perera Negrín

Silvio Ernesto Perea Rodríguez

Guillermo Skilton

Luis Javier GONZÁLEZ LÓPEZ

Ernesto J Podesta

Jeovanis Gil Valdes

Vladimir Besada Perez

Aniel Sanchez Puente

Jorge Fernandez De Cossio Dorta Duque

Lazaro Hiram Betancourt Nunez

Yassel Ramos Gomez

Luis Javier Gonzalez Lopez

A new compound of formula A for the treatment of aggressive and/or resistant tumors expressing acyl-CoA synthetase 4 (ACSL4) and/or depending on steroids action. More particularly, the compound of the present invention inhibits tumor growth in ACSL4-expressing breast and prostate cancers, inhibits steroid synthesis and sensitizes cells towards chemotherapeutic and hormone therapy agents. Pharmaceutical compositions comprising the ACSL4-inhibitory compound of the invention, pharmaceutical combinations thereof with other anticancer agents and use in therapy.

Acyl-CoA synthetase 4 (ACSL4) inhibitory compound

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Analogs of 1-desamino-8-D-arginyl vasopressin having the formula: wherein, X and Y are amino acids as defined herein, useful as an anti-diuretic or as an inhibitor of metastasis and cancer cell migration.

1-desamino-8-D-arginyl vasopressin analogs

The present invention relates to the use of 1-deamino-8-D-arginine vasopressin (desmopressin), or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing any of them, in the preparation of a medication which minimizes metastatic dissemination during cancer surgery. Additionally, the invention also relates to pharmaceutical compositions comprising the same and to a method of treating a mammal in order to inhibit metastatic spread during surgical extirpation of a cancer mass.

Method of inhibiting metastatic dissemination using desmopressin

Growing community of inventors

Buenos Aires, Argentina

Daniel Eduardo Gomez